UROwebinar: Module 1: CVD in prostate cancer patients – Increased risks & comorbidities
This online curriculum addresses the unmet needs in personalised management of Prostate Cancer patients with history and risk of CVD events and is initiated by The Canadian Urological Association, the International Cardio-Oncology Society together with the European Association of Urology.
The curriculum is divided in a series of educational online modules, each one consisting of pre-recorded sessions and a live webinar. During the first module the following topics will be addressed:
Presentation 1: The comorbidity burden in prostate cancer
1) What are the main comorbidities in men with prostate cancer and how do they affect the outcomes?
2) Which patient needs more assessment before making a decision on the treatment?
3) What are the major risks of CVD?
Presentation 2: Risk scoring of CVD in PCa patients undergoing hormonal PCa treatment
1) What is the impact of T decrease on CVD?
2) How do ADT and antiandrogens affect the CVD risk profile
3) What are novel hormonal treatments and how do they affect the CVD risk profile?
4)What CVD risk assessment tools are available
Live webinar: Case discussion with live Q&A
During the live webinar a practical assessment of cardiovascular risk in men with prostate cancer in the clinic will be presented. The various risk scoring systems will be discussed amongst the panellists with a practical review of the pros and cons.
You are recommended to watch the pre-recorded lectures as a preparation for the live webinar. Attending the live webinar is free (registration required) and if you join live you will receive accreditation points.
At a glance
Publication date: February 2021
Available languages: English
Topic: Prostate cancer
CME: 1 European CME credits (ECMEC)
Duration: Approx. 60 minutes
This educational activity has been funded by Ferring Pharmaceutical. The educational programme of this online activity has been a collaboration with Ferring Pharmaceutical, but independently developed and approved by the Canadian Urological Association, the International Cardio-Oncology Society together with the European Association of Urology